Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020

Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020

Summary

According to the recently published report 'Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020'; Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.
The report 'Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020' outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 8 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Toxicology, Cardiovascular, Gastrointestinal, Genetic Disorders, Hormonal Disorders, Metabolic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders and Women's Health which include indications Cancer Anorexia-Cachexia Syndrome, Growth Hormone Deficiency, Obesity, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Born Small For Gestational Age (SGA), Cachexia, Chemotherapy Effects, Chronic Kidney Disease (Chronic Renal Failure), Constipation, Diabetic Gastroparesis, Endocrine Gland Disorders, Fatigue, Ischemia, Prader-Willi Syndrome (PWS), Sepsis, Traumatic Brain Injury and Turner Syndrome.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
Allergan Ltd
AstraZeneca Plc
Extend Biosciences Inc
Helsinn Group
Lumos Pharma Inc
Millendo Therapeutics Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
TheraSource LLC
Zeria Pharmaceutical Co Ltd
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-12861903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-418 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibutamoren mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
livoletide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OXE-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GHSR for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
Featured News & Press Releases
Oct 21, 2020: Oxeia Biopharmaceuticals announces initiation of phase 2 trial for OXE103 for the treatment of concussions
Sep 16, 2020: Aeterna Zentaris provides corporate update
Sep 08, 2020: Aeterna Zentaris announced presentation of positive results from first pediatric study of Macimorelin at the 22nd European Congress of Endocrinology
Jul 31, 2020: Aeterna Zentaris announces continued expansion of intellectual property portfolio for Macimorelin with additional patent applications
Jul 30, 2020: Aeterna Zentaris announces abstract of results from first pediatric study of macimorelin accepted for presentation at the 22nd European Congress of Endocrinology
Apr 07, 2020: Aeterna Zentaris announces EMA decision to accept a modification to an agreed pediatric investigation plan for macimorelin
Apr 06, 2020: Millendo Therapeutics announces topline results for pivotal phase 2b study of Livoletide in patients with Prader-Willi Syndrome (PWS)
Apr 06, 2020: Aeterna Zentaris announces positive results in dose-finding pediatric study of macimorelin
Mar 12, 2020: Aeterna Zentaris announces settlement of previously disclosed class-action lawsuit
Feb 12, 2020: Aeterna Zentaris to present at Noble Capital Markets' 16th Annual Investor Conference
Jan 28, 2020: Aeterna Zentaris announces completion of patient recruitment in dose-finding pediatric study of Macimorelin
Dec 18, 2019: Aeterna Zentaris announces publication of GHD Management Guidelines
Nov 14, 2019: Millendo closes enrolment for first part of livoletide’s ZEPHYR trial
Nov 07, 2019: Millendo Therapeutics to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019
Sep 26, 2019: Millendo Therapeutics to present at Prader-Willi Syndrome Conferences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aeterna Zentaris Inc, H2 2020
Pipeline by Allergan Ltd, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Extend Biosciences Inc, H2 2020
Pipeline by Helsinn Group, H2 2020
Pipeline by Lumos Pharma Inc, H2 2020
Pipeline by Millendo Therapeutics Inc, H2 2020
Pipeline by Oxeia Biopharmaceuticals Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by RaQualia Pharma Inc, H2 2020
Pipeline by TheraSource LLC, H2 2020
Pipeline by Zeria Pharmaceutical Co Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
List of Figures
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook